Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$16.61
-0.46-2.69%
At close: -
$16.61
0.000.00%
After Hours: 4:36 PM EDT
Comments
Loading...
ACADIA Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ACAD | Benzinga
ACADIA Pharmaceuticals Inc has a consensus price target of $26.76 based on the ratings of 22 analysts. The high is $42 issued by Cantor Fitzgerald on August 22, 2023. The low is $19 issued by Oppenheimer on May 6, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, Cantor Fitzgerald, and HC Wainwright & Co. on March 7, 2025, February 27, 2025, and February 27, 2025, respectively. With an average price target of $25 between Morgan Stanley, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 50.51% upside for ACADIA Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Cantor Fitzgerald
HC Wainwright & Co.
Needham
Deutsche Bank
1calculated from analyst ratings
Analyst Ratings for ACADIA Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 20.41% | Morgan Stanley | Jeffrey Hung61% | $20 → $20 | Assumes | → Equal-Weight | Get Alert |
| 02/27/2025 | Buy Now | 68.57% | Cantor Fitzgerald | Charles Duncan71% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2025 | Buy Now | 62.55% | HC Wainwright & Co. | Andrew Fein62% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 68.57% | Needham | Ami Fadia60% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 32.45% | Deutsche Bank | Neena Bitritto-Garg60% | → $22 | Initiates | → Hold | Get Alert |
| 01/03/2025 | Buy Now | 20.41% | Guggenheim | Yatin Suneja46% | $20 → $20 | Downgrade | Buy → Neutral | Get Alert |
| 11/07/2024 | Buy Now | 68.57% | Needham | Ami Fadia60% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 62.55% | HC Wainwright & Co. | Andrew Fein62% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill9% | — | Reinstates | → Market Perform | Get Alert |
| 08/08/2024 | Buy Now | 38.47% | Citigroup | David Hoang42% | $30 → $23 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 38.47% | UBS | Ashwani Verma50% | $25 → $23 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 62.55% | HC Wainwright & Co. | Andrew Fein62% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 68.57% | Needham | Ami Fadia60% | $30 → $28 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 68.57% | Cantor Fitzgerald | Charles Duncan71% | $37 → $28 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 56.53% | RBC Capital | Gregory Renza47% | $29 → $26 | Maintains | Outperform | Get Alert |
| 08/07/2024 | Buy Now | 20.41% | Morgan Stanley | Jeffrey Hung61% | $28 → $20 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/12/2024 | Buy Now | 68.57% | Morgan Stanley | Jeffrey Hung61% | $30 → $28 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 86.63% | BMO Capital | Keith Tapper20% | → $31 | Initiates | → Outperform | Get Alert |
| 06/25/2024 | Buy Now | 74.59% | RBC Capital | Gregory Renza47% | $29 → $29 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2024 | Buy Now | 32.45% | B of A Securities | Tazeen Ahmad55% | $26 → $22 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 80.61% | Needham | Ami Fadia60% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 122.76% | Cantor Fitzgerald | Charles Duncan71% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 62.55% | HC Wainwright & Co. | Andrew Fein62% | $33 → $27 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 80.61% | Citigroup | David Hoang42% | $30.19 → $30 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 26.43% | Stifel | Paul Matteis44% | $26 → $21 | Maintains | Hold | Get Alert |
| 05/09/2024 | Buy Now | 26.43% | Mizuho | Uy Ear11% | $25 → $21 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 68.57% | Baird | Joel Beatty49% | $31 → $28 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 14.39% | Oppenheimer | Jay Olson22% | $19 → $19 | Maintains | Perform | Get Alert |
| 04/30/2024 | Buy Now | 62.55% | UBS | Ashwani Verma50% | $33 → $27 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | 122.76% | Cantor Fitzgerald | Charles Duncan71% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 04/10/2024 | Buy Now | 122.76% | Cantor Fitzgerald | Charles Duncan71% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 04/09/2024 | Buy Now | 92.66% | Needham | Ami Fadia60% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 50.51% | JP Morgan | Tessa Romero10% | $29 → $25 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 80.61% | Morgan Stanley | Jeffrey Hung61% | $40 → $30 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 81.76% | Citigroup | David Hoang42% | $38 → $30.19 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 80.61% | RBC Capital | Gregory Renza47% | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 50.51% | Mizuho | Uy Ear11% | $39 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 134.8% | JMP Securities | Jason Butler30% | $44 → $39 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 122.76% | Cantor Fitzgerald | Charles Duncan71% | $42 → $37 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 86.63% | Baird | Joel Beatty49% | $40 → $31 | Maintains | Outperform | Get Alert |
| 03/12/2024 | Buy Now | 14.39% | Oppenheimer | Jay Olson22% | $25 → $19 | Maintains | Perform | Get Alert |
| 03/12/2024 | Buy Now | 80.61% | B of A Securities | Tazeen Ahmad55% | $33 → $30 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | 98.68% | Canaccord Genuity | Sumant Kulkarni42% | $40 → $33 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 98.68% | HC Wainwright & Co. | Andrew Fein62% | → $33 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 92.66% | Needham | Ami Fadia60% | $36 → $32 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 74.59% | JP Morgan | Tessa Romero10% | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 98.68% | HC Wainwright & Co. | Andrew Fein62% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 152.86% | Cantor Fitzgerald | Charles Duncan71% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 02/28/2024 | Buy Now | 110.72% | RBC Capital | Gregory Renza47% | $36 → $35 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 134.8% | Mizuho | Uy Ear11% | $40 → $39 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 116.74% | Needham | Ami Fadia60% | $37 → $36 | Maintains | Buy | Get Alert |
| 02/07/2024 | Buy Now | 152.86% | JMP Securities | Jason Butler30% | $42 → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/05/2024 | Buy Now | 50.51% | Oppenheimer | Jay Olson22% | → $25 | Reiterates | Perform → Perform | Get Alert |
| 02/02/2024 | Buy Now | 152.86% | Cantor Fitzgerald | Charles Duncan71% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 01/30/2024 | Buy Now | 140.82% | Baird | Joel Beatty49% | → $40 | Initiates | → Outperform | Get Alert |
| 01/24/2024 | Buy Now | 122.76% | Needham | Joseph Stringer50% | → $37 | Upgrade | Hold → Buy | Get Alert |
| 12/29/2023 | Buy Now | 140.82% | Mizuho | Uy Ear11% | $35 → $40 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 140.82% | Morgan Stanley | Jeffrey Hung61% | $31 → $40 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/18/2023 | Buy Now | 62.55% | Stifel | Paul Matteis44% | $25 → $27 | Maintains | Hold | Get Alert |
| 12/14/2023 | Buy Now | 152.86% | Cantor Fitzgerald | Charles Duncan71% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | 50.51% | Deutsche Bank | Neena Bitritto-Garg60% | → $25 | Downgrade | Buy → Hold | Get Alert |
| 12/13/2023 | Buy Now | 128.78% | Citigroup | David Hoang42% | → $38 | Initiates | → Buy | Get Alert |
| 12/12/2023 | Buy Now | 50.51% | Deutsche Bank | Neena Bitritto-Garg60% | → $25 | Initiates | → Buy | Get Alert |
| 11/06/2023 | Buy Now | 140.82% | Canaccord Genuity | Sumant Kulkarni42% | $38 → $40 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | 110.72% | Mizuho | Uy Ear11% | $20 → $35 | Upgrade | Neutral → Buy | Get Alert |
| 11/03/2023 | Buy Now | 152.86% | JMP Securities | Jason Butler30% | $39 → $42 | Maintains | Market Outperform | Get Alert |
| 11/03/2023 | Buy Now | 98.68% | RBC Capital | Gregory Renza47% | $32 → $33 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 86.63% | Morgan Stanley | Jeffrey Hung61% | $30 → $31 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 98.68% | UBS | Ashwani Verma50% | → $33 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 92.66% | JP Morgan | Tessa Romero10% | $29 → $32 | Upgrade | Neutral → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 152.86% | Cantor Fitzgerald | Sarah James45% | → $42 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 74.59% | JP Morgan | Tessa Romero10% | $28 → $29 | Maintains | Neutral | Get Alert |
| 08/03/2023 | Buy Now | 128.78% | Canaccord Genuity | Sumant Kulkarni42% | $39 → $38 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | 80.61% | Morgan Stanley | Jeffrey Hung61% | $30 → $30 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 50.51% | Oppenheimer | Jay Olson22% | → $25 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | Buy Now | 98.68% | HC Wainwright & Co. | Andrew Fein62% | → $33 | Reiterates | Buy → Buy | Get Alert |
| 07/28/2023 | Buy Now | 50.51% | Oppenheimer | Jay Olson22% | $23 → $25 | Maintains | Perform | Get Alert |
| 07/17/2023 | Buy Now | 134.8% | Canaccord Genuity | Sumant Kulkarni42% | $28 → $39 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | 152.86% | Cantor Fitzgerald | Sarah James45% | $36 → $42 | Maintains | Overweight | Get Alert |
| 07/14/2023 | Buy Now | 98.68% | RBC Capital | Gregory Renza47% | $28 → $33 | Maintains | Outperform | Get Alert |
| 07/14/2023 | Buy Now | 62.55% | Citigroup | Neena Bitritto-Garg60% | $21.6 → $27 | Maintains | Neutral | Get Alert |
| 07/14/2023 | Buy Now | 80.61% | Morgan Stanley | Jeffrey Hung61% | $21 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 134.8% | JMP Securities | Jason Butler30% | $31 → $39 | Maintains | Market Outperform | Get Alert |
| 07/14/2023 | Buy Now | 38.47% | Oppenheimer | Jay Olson22% | $20 → $23 | Maintains | Perform | Get Alert |
| 07/14/2023 | Buy Now | 98.68% | HC Wainwright & Co. | Andrew Fein62% | $28 → $33 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | 26.43% | Morgan Stanley | Jeffrey Hung61% | $20 → $21 | Maintains | Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | 86.63% | JMP Securities | Jason Butler30% | $23 → $31 | Maintains | Market Outperform | Get Alert |
| 06/14/2023 | Buy Now | 20.41% | Mizuho | Uy Ear11% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 06/14/2023 | Buy Now | 68.57% | HC Wainwright & Co. | Andrew Fein62% | → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 56.53% | B of A Securities | Tazeen Ahmad55% | $23 → $26 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | 98.68% | Cantor Fitzgerald | Sarah James45% | → $33 | Reiterates | → Overweight | Get Alert |
| 05/09/2023 | Buy Now | 62.55% | RBC Capital | Gregory Renza47% | → $27 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 38.47% | JMP Securities | Jason Butler30% | $22 → $23 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 68.57% | HC Wainwright & Co. | Andrew Fein62% | → $28 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | 30.04% | Citigroup | Neena Bitritto-Garg60% | $21 → $21.6 | Maintains | Neutral | Get Alert |
| 04/14/2023 | Buy Now | 20.41% | Mizuho | Uy Ear11% | → $20 | Reiterates | → Neutral | Get Alert |
| 03/20/2023 | Buy Now | 26.43% | JP Morgan | Tessa Romero10% | $19 → $21 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 38.47% | B of A Securities | Tazeen Ahmad55% | → $23 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 20.41% | Morgan Stanley | Jeffrey Hung61% | $19 → $20 | Maintains | Equal-Weight | Get Alert |
| 03/14/2023 | Buy Now | 62.55% | RBC Capital | Gregory Renza47% | → $27 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for ACADIA Pharmaceuticals (ACAD) stock?
The latest price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) was reported by Morgan Stanley on March 7, 2025. The analyst firm set a price target for $20.00 expecting ACAD to rise to within 12 months (a possible 20.41% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ACADIA Pharmaceuticals (ACAD)?
The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) was provided by Morgan Stanley, and ACADIA Pharmaceuticals their equal-weight rating.
When was the last upgrade for ACADIA Pharmaceuticals (ACAD)?
The last upgrade for ACADIA Pharmaceuticals Inc happened on January 24, 2024 when Needham raised their price target to $37. Needham previously had a hold for ACADIA Pharmaceuticals Inc.
When was the last downgrade for ACADIA Pharmaceuticals (ACAD)?
The last downgrade for ACADIA Pharmaceuticals Inc happened on January 3, 2025 when Guggenheim changed their price target from $20 to $20 for ACADIA Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ACADIA Pharmaceuticals (ACAD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating ACADIA Pharmaceuticals (ACAD) correct?
While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a with a price target of $20.00 to $20.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $16.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.